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Ginseng is one of the most widely used herbal medicines in the world. It has been
used in the treatment of various ailments and to boost immunity for centuries; especially
in Asian countries. The most common ginseng variant in traditional herbal medicine is
ginseng, which is made from the peeled and dried root of Panax Ginseng. Ginseng
has been suggested as an effective treatment for a vast array of neurological disorders,
including stroke and other acute and chronic neurodegenerative disorders. Ginseng’s
neuroprotective effects are focused on the maintenance of homeostasis. This review
involves a comprehensive literature search that highlights aspects of ginseng’s putative
neuroprotective effectiveness, focusing on stroke. Attenuation of inflammation through
inhibition of various proinflammatory mediators, along with suppression of oxidative
stress by various mechanisms, including activation of the cytoprotective transcriptional
factor Nrf2, which results in decrease in reactive oxygen species, could account for its
neuroprotective efficacy. It can also prevent neuronal death as a result of stroke, thus
decreasing anatomical and functional stroke damage. Although there are diverse studies
that have investigated the mechanisms involved in the efficacy of ginseng in treating
disorders, there is still much that needs to be clarified. Both in vitro and in vivo studies
including randomized controlled clinical trials are necessary to develop in-depth knowledge
of ginseng and its practical applications.
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INTRODUCTION
Ginseng is a broad term that refers to a group of 11 species
of perennial plants belonging to the Panax genus under the
family Araliaceae. The commercially available herbal formula-
tions of ginseng are extracted from the root of these plants.
It has been used for more than 2000 years mainly in China,
Korea and Japan. The most commonly used herbal deriva-
tive of ginseng is Korean ginseng which is derived from the
peeled, steamed, and dried root of Panax ginseng also com-
monly known as Korean ginseng. Although there are other
variants of ginseng that contain many of the same compounds
and medicinal properties, we will mainly focus on Panax gin-
seng and its constituents. The chemical constituents of ginseng
include triterpene saponins, polysaccharides, peptidoglycans,
nitrogen-containing compounds, fatty acids, carbohydrates and
phenolic compounds (Sticher, 1998). It also contains essential
oil-containing polyacetylenes and sesquiterpenes (Sticher, 1998).
Ginsenosides are the major active components in ginseng; they
are a form of triterpene glycosides (saponins). Of the 150 gin-
senosides that have been isolated from ginseng, 40 have been
found in Panax ginseng alone (Christensen, 2009). These mainly
include Rb1, Rb2, Rc, Rd, Rg1, Rg2, Rh1, and Re (Attele et al.,
1999).
The Greek word “panax” means “cure-all” and true to its
name, ginseng has proven to have a wide variety of medicinal
uses. Ginseng can improve pulmonary lung function in sta-
ble chronic obstructive pulmonary disorder patients (An et al.,
2011). Korean ginseng has been shown to provide symptomatic
relief in the patients with complaints of erectile dysfunction
(Hong et al., 2002). A large number of carcinomas, includ-
ing those associated with smoking, could potentially be pre-
vented by the regular use of ginseng (Yun and Choi, 1995).
Ginseng’s efficacy in type-2 diabetics has been illustrated by
the fact that the patients had a decrease in the fasting blood
glucose, weight loss and HbA1c (glycated hemoglobin) along
with improvement in mood and psychophysical performance
(Sotaniemi et al., 1995). Ginseng also possesses numerous
cardiovascular benefits that are mainly due to its cardio-
protective and anti-hypertensive effects; it can also attenuate
myocardial hypertrophy and heart failure (Karmazyn et al.,
2011).
Ginseng is also known to affect various aspects of neu-
rodevelopmental, neurodegenerative and neuropsychiatric dis-
orders (Kim et al., 2013). Stroke is the 4th leading cause
of death in United States with an estimated 1 death every
4 min. Stroke recurs in 1 out of every 4 stroke patients.
Approximately 87% of strokes are a result of ischemic insult
and 13% are hemorrhagic strokes. Subarachnoid hemorrhage
(SAH) accounts for approximately 3% of all strokes, has an
incidence rate of 30,000 cases per year (King, 1997) and is
Frontiers in Cellular Neuroscience www.frontiersin.org January 2015 | Volume 8 | Article 457 | 1
Rastogi et al. Ginseng and neuroprotection in stroke
Ta
b
le
1
|A
n
at
o
m
ic
al
an
d
b
eh
av
io
ra
le
ff
ec
ts
o
f
va
ri
o
u
s
g
in
se
n
g
ex
tr
ac
ts
o
n
in
vi
vo
ce
re
b
ra
li
sc
h
em
ia
m
o
d
el
s.
M
o
d
el
G
in
se
n
o
si
d
e
S
p
ec
ie
s
D
o
sa
ge
A
n
at
o
m
ic
al
A
ss
es
sm
en
t
B
eh
av
io
ra
l
R
ef
er
en
ce
an
d
ro
u
te
o
u
tc
o
m
e
ti
m
e
af
te
r
o
u
tc
o
m
e
su
rg
er
y
M
C
A
O
(2
h)
R
b1
R
at
s
40
m
g/
kg
IV
3
an
d
12
h,
1,
2,
3,
5
an
d
10
da
ys
D
ec
re
as
e
m
N
S
S
G
ao
et
al
.(
20
10
)
M
C
A
O
(2
h)
K
R
G
R
at
s
10
0
m
g/
kg
/d
ay
P
O
1,
3,
an
d
7
da
ys
D
ec
re
as
e
m
N
S
S,
co
rn
er
te
st
B
an
et
al
.(
20
12
)
M
C
A
O
(p
er
m
an
en
t)
dg
R
b1
S
tr
ok
e-
pr
on
e
Im
m
ed
ia
te
ly
po
st
-M
C
A
O
To
ta
li
nf
ar
ct
2
an
d
4
w
ee
ks
D
ec
re
as
e
M
or
ris
S
ak
an
ak
a
et
al
.(
20
07
)
(D
ih
yd
ro
gi
ns
en
os
id
e
sp
on
ta
ne
ou
sl
y
IV
bo
lu
s
of
60
µ
l
vo
lu
m
e
de
cr
ea
se
w
at
er
m
az
e
te
st
R
b1
)
hy
pe
rt
en
si
ve
(0
.6
or
6
µ
g/
60
µ
l)
ra
ts
(S
H
R
-S
P
)
fo
llo
w
ed
by
m
ai
nt
en
an
ce
IV
do
se
of
(0
.6
or
6
µ
g/
da
y)
M
C
A
O
(2
h)
R
h2
R
at
s
R
h2
an
d
ac
id
tr
ea
te
d
gi
ns
en
g
P
O
To
ta
li
nf
ar
ct
vo
lu
m
e
de
cr
ea
se
Pa
rk
et
al
.(
20
04
)
M
C
A
O
(2
h)
Fe
rm
en
te
d
gi
ns
en
g
R
at
s
Fe
rm
en
te
d
gi
ns
en
g
an
d
gi
ns
en
g
P
O
To
ta
li
nf
ar
ct
vo
lu
m
e
de
cr
ea
se
B
ae
et
al
.(
20
04
)
M
C
A
O
(3
0
m
in
)
C
om
po
un
d
K
M
ic
e
30
m
g/
kg
IP
To
ta
li
nf
ar
ct
vo
lu
m
e
de
cr
ea
se
Pa
rk
et
al
.(
20
12
)
M
C
A
O
(p
er
m
an
en
t)
R
b1
S
H
R
-S
P
R
at
s
Im
m
ed
ia
te
ly
po
st
-M
C
A
O
To
ta
li
nf
ar
ct
2
an
d
4
w
ee
ks
D
ec
re
as
e
M
or
ris
Zh
an
g
et
al
.(
20
06
)
IV
bo
lu
s
of
vo
lu
m
e
de
cr
ea
se
.
w
at
er
m
az
e
te
st
(6
or
60
µ
g/
60
µ
L)
Pr
ev
en
tio
n
of
fo
llo
w
ed
by
co
rt
ic
al
in
fa
rc
tio
n
m
ai
nt
en
an
ce
IV
do
se
an
d
se
co
nd
ar
y
of
(6
or
60
µ
g/
da
y)
th
al
am
ic
de
ge
ne
ra
tio
n
M
C
A
O
(p
er
m
an
en
t)
K
R
G
S
H
R
-S
P
R
at
s
0.
00
6–
6.
0
µ
g/
d
IV
To
ta
li
nf
ar
ct
vo
lu
m
e
de
cr
ea
se
2
an
d
4
w
ee
ks
D
ec
re
as
e
M
or
ris
w
at
er
m
az
e
te
st
Zh
an
g
et
al
.(
19
98
)
M
C
A
O
(2
h)
K
R
G
R
at
s
10
0
m
g/
kg
/d
ay
P
O
To
ta
li
nf
ar
ct
vo
lu
m
e
de
cr
ea
se
1,
3,
an
d
7
da
ys
D
ec
re
as
e
m
N
S
S,
co
rn
er
tu
rn
te
st
Le
e
et
al
.(
20
11
)
M
C
A
O
(9
0
m
in
)
R
b1
R
at
s
12
.5
m
g/
kg
IN
or
IV
To
ta
li
nf
ar
ct
vo
lu
m
e
de
cr
ea
se
Lu
et
al
.(
20
11
)
M
C
A
O
(2
h)
R
b1
R
at
s
12
.5
m
g/
kg
IN
To
ta
li
nf
ar
ct
vo
lu
m
e
de
cr
ea
se
6,
24
an
d
72
h
D
ec
re
as
e
m
N
S
S
Zh
u
et
al
.(
20
12
)
M
C
A
O
(p
er
m
an
en
t)
R
b1
,R
g1
R
at
s
R
b1
10
,2
0,
40
m
g/
kg
IV
R
b1
de
cr
ea
se
in
fa
rc
t
si
ze
24
h
D
ec
re
as
e
R
b1
N
D
S,
Zh
an
g
an
d
Li
u
(1
99
6)
M
C
A
O
(2
h)
R
g1
40
m
g/
kg
IV
R
g1
in
ef
fe
ct
iv
e
In
ef
fe
ct
iv
e
R
g1
N
D
S
M
C
A
O
(2
h)
B
la
ck
gi
ns
en
g
R
at
s
10
0,
40
0
m
g/
kg
P
O
2
w
ee
ks
D
ec
re
as
e
M
or
ris
w
at
er
m
az
e
te
st
Pa
rk
et
al
.(
20
11
)
(C
on
tin
ue
d)
Frontiers in Cellular Neuroscience www.frontiersin.org January 2015 | Volume 8 | Article 457 | 2
Rastogi et al. Ginseng and neuroprotection in stroke
Ta
b
le
1
|C
o
n
ti
n
u
ed
M
o
d
el
G
in
se
n
o
si
d
e
S
p
ec
ie
s
D
o
sa
ge
A
n
at
o
m
ic
al
A
ss
es
sm
en
t
B
eh
av
io
ra
l
R
ef
er
en
ce
an
d
ro
u
te
o
u
tc
o
m
e
ti
m
e
af
te
r
o
u
tc
o
m
e
su
rg
er
y
M
C
A
O
(p
er
m
an
en
t)
G
in
se
ng
to
ta
l
sa
po
ni
ns
R
at
s
25
m
g/
kg
IP
1,
3,
7
an
d
14
da
ys
D
ec
re
as
e
N
D
S
Zh
en
g
et
al
.(
20
11
)
M
C
A
O
(2
h)
R
d
R
at
s
D
os
e
de
pe
nd
en
t
st
ud
y
In
fa
rc
t
si
ze
1,
3,
7,
14
,
D
os
e
de
pe
nd
en
t
Ye
et
al
.(
20
11
a)
M
C
A
O
(p
er
m
an
en
t)
1–
50
m
g/
kg
IV
de
cr
ea
se
fr
om
21
,2
8,
an
d
42
da
ys
im
pr
ov
em
en
ts
in
10
m
g/
kg
to
m
N
S
S,
m
od
ifi
ed
50
m
g/
kg
at
di
ffe
re
nt
st
ic
ky
ta
pe
te
st
,
tim
e-
po
in
ts
.
co
rn
er
te
st
In
fa
rc
t
si
ze
de
cr
ea
se
w
ith
R
d
at
2h
(3
6–
44
%
)o
r
4
h
(3
1–
40
%
),
bu
t
no
ch
an
ge
at
or
af
te
r
8
h
in
M
C
A
O
(2
h)
.
In
fa
rc
t
si
ze
de
cr
ea
se
af
te
r
pe
rm
an
en
t
M
C
A
O
M
C
A
O
(1
h)
R
d
M
ic
e
0.
1–
20
0
m
g/
kg
IP
in
In
fa
rc
t
vo
lu
m
e
1
an
d
14
da
ys
1)
D
ec
re
as
e
in
Ye
et
al
.(
20
11
b)
do
se
re
sp
on
se
st
ud
y
de
cr
ea
se
w
ith
a
B
at
te
ry
50
m
g/
kg
IP
in
gr
ea
te
st
at
50
m
g/
kg
of
2
te
st
s
Po
st
ur
al
th
er
ap
eu
tic
w
in
do
w
w
hi
le
th
e
0.
1,
1
an
d
re
fle
x
te
st
,
st
ud
y
20
0
m
g/
kg
w
er
e
Fo
re
lim
b
in
ef
fe
ct
iv
e.
pl
ac
in
g
te
st
In
fa
rc
t
vo
lu
m
e
bo
rd
er
lin
e
de
cr
ea
se
w
ith
(B
el
ay
ev
et
al
.,
19
96
);
R
d
at
2h
(3
6.
3%
)
2)
In
cr
ea
se
in
a
B
at
te
ry
or
4
h
(3
4.
6%
)
of
6
te
st
s
bu
t
no
ch
an
ge
at
8
h.
(G
ar
ci
a
et
al
.,
19
95
),
in
cr
ea
se
.
M
C
A
O
(2
h)
R
d
R
at
s
0.
1–
20
0
m
g/
kg
IP
In
fa
rc
t
vo
lu
m
e
1,
3,
7,
14
,
D
ec
re
as
e
m
N
S
S
Ye
et
al
.(
20
11
c)
de
cr
ea
se
gr
ea
te
st
at
21
,2
8,
an
d
42
da
ys
50
m
g/
kg
at
da
y
1
w
hi
le
th
e
0.
1,
1
an
d
20
0
m
g/
kg
do
se
s
w
er
e
in
ef
fe
ct
iv
e
(C
on
tin
ue
d)
Frontiers in Cellular Neuroscience www.frontiersin.org January 2015 | Volume 8 | Article 457 | 3
Rastogi et al. Ginseng and neuroprotection in stroke
Ta
b
le
1
|C
o
n
ti
n
u
ed
M
o
d
el
G
in
se
n
o
si
d
e
S
p
ec
ie
s
D
o
sa
ge
A
n
at
o
m
ic
al
A
ss
es
sm
en
t
B
eh
av
io
ra
l
R
ef
er
en
ce
an
d
ro
u
te
o
u
tc
o
m
e
ti
m
e
af
te
r
o
u
tc
o
m
e
su
rg
er
y
M
C
A
O
(2
h)
R
d
R
at
s
50
m
g/
kg
IP
To
ta
li
nf
ar
ct
1
an
d
14
da
ys
1)
D
ec
re
as
e
in
a
B
at
te
ry
Ye
et
al
.(
20
11
d)
vo
lu
m
e
de
cr
ea
se
of
2
te
st
s
(B
el
ay
ev
et
al
.,
19
96
),
2)
In
cr
ea
se
in
a
B
at
te
ry
of
6
te
st
s
(G
ar
ci
a
et
al
.,
19
95
)
M
C
A
O
(2
h)
R
g1
R
at
s
20
m
g/
kg
IP
6
h,
1,
3,
7
an
d
14
da
ys
D
ec
re
as
e
N
D
S
Zh
ou
et
al
.(
20
14
)
M
C
A
O
(2
h)
R
b1
R
at
s
20
,4
0,
80
m
g/
kg
To
ta
li
nf
ar
ct
vo
lu
m
e
de
cr
ea
se
D
ec
re
as
e
N
D
S
Li
u
et
al
.(
20
13
)
M
C
A
O
(1
h)
G
in
se
ng
M
ic
e
36
0
m
g/
kg
To
ta
li
nf
ar
ct
vo
lu
m
e
de
cr
ea
se
B
et
te
r
R
ot
ar
od
sc
or
es
C
he
on
et
al
.(
20
13
)
M
C
A
O
(2
h)
R
d
R
at
s
30
m
g/
kg
IP
1
h
be
fo
re
M
C
A
O
,
10
m
g/
kg
O
D
un
til
sa
cr
ifi
ce
To
ta
li
nf
ar
ct
vo
lu
m
e
de
cr
ea
se
,
R
ed
uc
tio
n
in
hi
pp
oc
am
pa
l
tis
su
e
lo
ss
Po
st
-o
pe
ra
tiv
e
da
ys
26
–3
2
Im
pr
ov
ed
pe
rf
or
m
an
ce
in
M
or
ris
W
at
er
M
az
e
an
d
N
ov
el
O
bj
ec
t
R
ec
og
ni
tio
n
Te
st
Zh
an
g
et
al
.(
20
14
)
B
C
C
A
O
(3
m
in
or
3.
5
m
in
)
R
b1
G
er
bi
ls
Im
m
ed
ia
te
ly
po
st
-B
C
C
A
O
,
IV
bo
lu
s
of
2
µ
L
(2
.5
or
25
ng
/2
µ
L)
fo
llo
w
ed
by
m
ai
nt
en
an
ce
IV
(6
0
or
60
0
ng
/d
ay
)I
P
7
da
y
S
te
p-
do
w
n
Pa
ss
iv
e
av
oi
da
nc
e
ta
sk
m
et
ho
d,
In
cr
ea
se
Li
m
et
al
.(
19
97
)
B
C
C
A
O
(5
m
in
)
R
b1
,R
g1
,R
o
G
er
bi
ls
G
in
se
ng
po
w
de
r
(R
G
P
)(
0.
6,
0.
9
or
1.
5
g/
kg
P
O
C
ru
de
gi
ns
en
g
sa
po
ni
n
(C
G
S
)
an
d
C
ru
de
gi
ns
en
g
no
-s
ap
on
in
(C
G
N
S
)
(b
ot
h
50
or
10
0
m
g/
kg
)I
P
R
b1
,R
g1
,R
o
(1
0
or
20
m
g/
kg
fo
r
ea
ch
)I
P
7
da
y
Pa
ss
iv
e
av
oi
da
nc
e
ta
sk
.
R
G
P,
C
G
S,
C
G
N
S
(1
00
m
g/
kg
),
R
b1
pr
ei
sc
he
m
ic
do
se
in
cr
ea
se
.
Po
st
is
ch
em
ic
R
G
P,
C
G
S
or
R
b1
w
as
in
ef
fe
ct
iv
e
W
en
et
al
.(
19
96
)
Th
ro
m
bo
em
bo
lic
R
b1
M
on
ke
ys
30
0
µ
g/
kg
IV
B
ra
in
ed
em
a
1,
6,
an
d
24
h
N
D
S
de
cr
ea
se
Yo
sh
ik
aw
a
et
al
.(
20
08
)
st
ro
ke
de
cr
ea
se
an
d
2,
4,
an
d
7
da
ys
of
le
ft
M
C
A
IN
:i
nt
ra
na
sa
l;
IP
:I
nt
ra
pe
rit
on
ea
l,
IV
:I
nt
ra
ve
no
us
,m
N
S
S
:m
od
ifi
ed
N
eu
ro
lo
gi
ca
lS
ev
er
ity
S
co
re
,N
D
S
:N
eu
ro
lo
gi
ca
lD
efi
ci
t
S
co
re
,N
IH
S
S
:N
at
io
na
lI
ns
tit
ut
es
of
H
ea
lth
S
tr
ok
e
S
ca
le
,O
D
:O
nc
e
D
ai
ly
,P
O
:P
er
or
al
.
Frontiers in Cellular Neuroscience www.frontiersin.org January 2015 | Volume 8 | Article 457 | 4
Rastogi et al. Ginseng and neuroprotection in stroke
mostly seen after brain aneurysm rupture or in traumatic brain
injury (TBI) patients. Stroke is also one of the leading causes
of long term disability (Go et al., 2013). These are reasons
for stroke’s high magnitude of mortality and morbidity. From
this information, one can see that present preventive and treat-
ment strategies are not sufficient to curb this health menace.
Because of this, there is a need to look for other treatment
modalities and ginseng has shown promising evidence in this
regard.
PUTATIVE GINSENG NEUROPROTECTION AND
MECHANISMS OF ACTION IN STROKE
The role of ginseng and its saponins in stroke prevention and
treatment has been an area of great interest for researchers. The
studies have elucidated various mechanisms contributing to the
efficacy of ginseng in ischemic stroke.
ANTI-INFLAMMATORY EFFECTS
Perhaps the most intriguing property of ginseng is its anti-
inflammatory effect. Microglial activation plays an important role
in inflammation as it develops many properties of macrophages.
Activated microglia have both pro- and anti-inflammatory prop-
erties (Iadecola and Anrather, 2011). It has two activated phe-
notypes: M1, which is pro-inflammatory and is activated by
inciting factors such as stress, inflammatory challenge, and M2,
which is anti-inflammatory and is activated by anti-inflammatory
cytokines such as interleukin 4 (IL-4; Rojo et al., 2014). The M2
phenotype plays a role in post-ischemic inflammation resolution
and tissue repair through secreting mediators such as transform-
ing growth factor-β (TGF-β) and IL-10 (Denes et al., 2007). The
pro-inflammatory role of M1 is mediated by various inflamma-
tory mediators including reactive oxygen intermediates, nitric
oxide (NO), proteases (Colton and Gilbert, 1987; Banati et al.,
1993a,b), and cytokines including IL-1, IL-6, and interferon-
γ (IFN-γ; Sawada et al., 1989; Dickson et al., 1993; Kleinig
and Vink, 2009). Ginsenoside Rb1 has been shown to repress
microglial M1 activation and decrease the pro-inflammatory
cytokines IL-6 in a transient middle cerebral artery occlusion
(MCAO) rat model. Zhu et al. found a decrease in the total infarct
volume and modified Neurological Severity Score (mNSS) on
intranasal administration of 12.5 mg/kg ginsenoside Rb1 (Zhu
et al., 2012). Ginsenoside Rd and compound K (a metabolite
of ginseng saponins) also decrease microglial M1 activation (Ye
et al., 2011c; Park et al., 2012). Ye et al. demonstrated a decrease
in infarct volume and mNSS on intraperitoneal (IP) admin-
istration of 50 mg/kg ginsenoside Rd in the transient MCAO
rat model (Ye et al., 2011c). Park et al. also showed that IP
administration of 30 mg/kg compound K to the transient MCAO
mice model can decrease the total infarct volume (Park et al.,
2012).
Nuclear factor-κB (NF-κB) is a transcriptional pathway
involved in the regulation of inflammation through the expres-
sion of genes such as cycloygenase-2 (COX-2), inducible nitric
oxide synthase (iNOS), IL-6 (Baeuerle and Henkel, 1994). Gin-
senoside Rb1 suppresses total as well as phosphorylated NF-κB
and inhibits its DNA binding activity which in turn suppresses
neuronal death (Schneider et al., 1999) as well as decreases
IL-6 levels (Wang et al., 2007) in the brain (Zhu et al., 2012).
Compound K can also suppress the NF-κB pathway in mice
(Park et al., 2012). Lee et al. injected healthy mice with a single
dose of IP 3 mg/kg lipopolysaccharide to activate microglia and
subsequently inflammation. In the treatment group ginsenoside
Rb1 was administered orally at a dose of 10 or 20 mg/kg 1 h
prior to lipopolysaccharide injection. Similar to the other studies
they found that ginsenoside Rb1 prevents this microglial acti-
vation and subsequent release of pro-inflammatory cytokines
such as IL-1β, IL-6, and pro-inflammatory COX-2 enzyme at
a dosage of 20 mg/kg (Lee et al., 2013). COX-2 overexpres-
sion has also been linked to neuronal death post-ischemia in
the ischemic areas as well as in the surrounding areas through
an increase in the synthesis of prostaglandins (Nogawa et al.,
1997; Sairanen et al., 1998; Doré et al., 2003). Ginsenoside Rd
decreases the activity of COX-2 by directly decreasing COX-2
levels, so it can prevent ischemic death of neurons (Ye et al.,
2011c). Like COX-2, iNOS also catalyzes the formation of the
inflammatory mediator NO and its expression has been thought
to be mainly in the cells involved in the inflammation such
as microglia, astrocytes (Wang et al., 2007). Ginsenoside Rd
has been shown to inhibit iNOS, thus decreasing NO pro-
duction which decreases inflammation post-ischemia (Ye et al.,
2011c).
Mitogen-activated protein kinase (MAPK) and the proline-
directed kinases are another group of enzymes that enhance
the formation of pro-inflammatory proteins along with other
functions (Kyriakis and Avruch, 2001). Compound K, a metabo-
lite of ginseng inhibits phosphorylation of MAPKs in mice,
thus inhibiting their activation; this translates into decreased
production of pro-inflammatory proteins (Park et al., 2012).
The p38 MAPK can cause down-regulation of heme oxyge-
nase 1 (HO-1) expression, which is a rate-controlling enzyme
for heme metabolization (Tenhunen et al., 1968; Naidu et al.,
2009). HO-1 in itself has potent anti-inflammatory, antioxidant
and anti-apoptotic properties (Naidu et al., 2009; Gozzelino
et al., 2010). HO-1 can suppress NF-κB, and consequently it can
inhibit IL-1β expression which is pro-inflammatory (Rushworth
et al., 2008). Compound K treated mice showed an enhance-
ment in HO-1 expression for resolution of inflammation in
activated microglia (Park et al., 2012). Lee et al. used Korean
ginseng instead of individual components such as ginsenoside
Rd and ginsenoside Rb1; they also showed that it possesses anti-
inflammatory properties similar to its components when admin-
istered at 100 mg/kg orally to transient MCAO rat models (Lee
et al., 2011).
One of the major causes of morbidity and mortality post-
stroke is cerebral edema. Blood brain barrier disruption plays
a major role in the causation of the edema. Ginsenoside Rg1
prevents the disruption of this barrier by inhibiting the expres-
sion of aquaporin 4. When IP ginsenoside Rg1 treatment at a
dosage of 20 mg/kg was given in combination with acetazo-
lamide (an aquaporin 4 reversible inhibitor) (Tanimura et al.,
2009), neurological recovery was greater than when administered
alone to the transient MCAO rat models (Zhou et al., 2014).
Astrocytes are the most abundant glial cells; they have neuronal
supportive effects during normal conditions but during ischemia
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or injury they act pro-inflammatory and cause tissue scar for-
mation (Hayakawa et al., 2010). Yoshikawa et al. showed that
300 µg/kg intravenous (IV) ginsenoside Rb1 decreases cerebral
edema and inhibits delayed neuronal death post-ischemic insult
through the inhibition of astrocyte activity in the peri-infarct
region in thromboembolic stroke in monkeys (Yoshikawa et al.,
2008).
ANTI-APOPTOTIC EFFECTS
Another important role of ginseng is the inhibition of apoptosis
or delayed cell death. Bcl-2 is the major anti-apoptotic protein
which is located mainly on the outer membrane of mitochon-
dria; (Monaghan et al., 1992; Reed, 1997) this delineates the
importance of mitochondria in apoptosis. Bcl-2-associated X
protein (BAX) is the major pro-apoptotic protein that homod-
imerizes and heterodimerizes with Bcl-2, such that a reci-
procity exists between both BAX and Bcl-2 (Oltvai et al.,
1993). The dynamic balance between Bcl-2 and BAX plays
a major role in regulating apoptosis. Ginsenoside Rb1 when
administered at a dosage of 30 mg/kg IP to transient MCAO
rat models has been shown to increase Bcl-2 protein and
decrease BAX protein in rats (Yuan et al., 2007). Zhang et al.
also showed that ginsenoside Rg2 increased Bcl-2 protein and
decrease BAX protein when given to transient MCAO rat
models at a dose of 2.5, 5 and 10 mg/kg IV (Zhang et al.,
2008).
Cytochrome c, a small heme protein mainly located on
inner membrane of mitochondria, is linked to the respira-
tory chain complex. It also plays an important role in apop-
tosis (Gonzales and Neupert, 1990). Apoptotic cells show
an increase in cytosolic cytochrome c with a corresponding
decrease in mitochondrial one, Bcl-2 overexpression can pre-
vent this efflux to the cytosol, thus preventing apoptosis (Yang
et al., 1997). Liang et al. used human neuroblastoma SH-SY5Y
cells and exposed them to oxygen-glucose deprivation. They
showed that ginsenoside Rb1 at 1 and 10 µmol/l concentration
inhibits apoptosis by impeding cytochrome c and apoptosis-
inducing factor (AIF) release from mitochondria (Liang et al.,
2013). Apoptotic stimuli induce cytochrome c production which
causes conversion of pro caspase-3 into active caspase-3, thus
causing cell death (Reed, 1997). Caspase 3 is a protease
involved in the cleavage of substrates that results in apop-
tosis (Nicholson and Thornberry, 1997); it can also potenti-
ate apoptosis by causing release of cytochrome c as well as
by conversion of anti-apoptotic Bcl-2 into pro-apoptotic by
cleaving its carboxy-terminal (Cheng et al., 1997). Ginseno-
side Rd’s anti-apoptotic properties are evident by the fact
that it attenuates mitochondrial release of AIF, caspase 3 and
cytochrome c during transient MCAO in rats when given in
dose of 50 mg/kg IP, thus decreasing the total infarct vol-
ume (Ye et al., 2011d). Ginsenoside Rb1 also decreases the
activity of caspase-3 as demonstrated by Gao et al. when
they administered 40 mg/kg ginsenoside Rb1 IV to transient
MCAO rat models (Gao et al., 2010), thus inhibiting cell death
post-ischemia.
Various other proteins inhibit apoptosis such as neuronal
AIF, which inactivates caspase-3 and caspase-7, ginsenoside Rb1
increases the expression of neuronal apoptosis inhibitory protein
in rats (Yuan et al., 2007). Heat shock protein 70 is another
apoptosis inhibitory protein that has been shown to prolong
survival post-ischemic insult through a decrease in cytochrome
c release, which subsequently inhibits the down-stream apop-
totic pathway (Tsuchiya et al., 2003). Ginsenoside Rg2-treated
rats showed an increase in heat shock protein 70 expression
post-ischemia which underlines its anti-apoptotic role (Zhang
et al., 2008). Other examples include tumor suppressor pro-
tein p53, which has been associated with apoptosis in response
to brain ischemia (Morrison et al., 1996) or injury, proba-
bly through BAX activation (Miyashita and Reed, 1995). The
p53 expression was decreased in rats after ginsenoside Rg2
administration at various doses, which might be another reason
for its protective effect (Zhang et al., 2008). Thus, ginseno-
side Rg2 can potentially prevent vascular dementia which is
a long term sequel of ischemic stroke, by inhibiting neuronal
apoptosis post-acute ischemic insult (Zhang et al., 2008). Neu-
rotrophic factors are some proteins required for cell survival,
growth, and maintenance; ginsenoside Rb1 also increases the
expression and regulation of brain-derived neurotrophic fac-
tor (BDNF; Gao et al., 2010), and glial-derived neurotrophic
factors (GDNF) during transient MCAO in rats (Yuan et al.,
2007).
ANTI-OXIDATIVE EFFECTS
Attenuation of oxidative stress might be another explanation
for ginseng’s neuroprotective effects as described above. Oxida-
tive stress is the accumulation of reactive oxygen species (ROS)
due to its decreased degradation; these ROS can damage lipids,
DNA, RNA and proteins leading to neuronal dysfunction and
cell death. ROS can also cause the peroxidation of lipids because
lipids are present in biomembranes, thus damaging neuronal
structure. Lipid peroxides can be reduced by glutathione per-
oxidase, thus protecting the neurons. ROS are released in
excessive amounts from the microglia M1 phenotype. ROS in
turn cause the activation of the transcriptional factor Nrf2
[originally named: nuclear factor (erythroid-derived 2)-like 2],
which plays a vital role in various cell properties and notably
bringing back the microglia to the steady state (Rojo et al.,
2014).
Nrf2 is the major transcription factor that binds to the
antioxidant response element (ARE), which in itself is a multiple
gene regulator, also including genes for phase 2 enzymes (Chen
and Kunsch, 2004; Leonardo and Doré, 2011). In normal body
dynamics, Nrf2 is bound to kelch-like ECH-associated protein
1 (Keap1) and is inactivated. During stress, Keap1 disseminates
from Nrf2 (Itoh et al., 1999) and translocates in the nucleus
and thus Nrf2 causes initiation of ARE pathway mediated cyto-
protection (Wang et al., 2013; Figure 1). This activated Nrf2
restores microglia’s steady state by regulation of ARE-associated
genes such as enzymes involved in the degradation of ROS,
including SOD, glutathione peroxidase and enzymes involved
in synthesis of reducing factors such as glucose-6 phosphate
dehydrogenase [involved in synthesis of reduced nicotinamide
adenine dinucleotide phosphate (NADPH)]. Other genes include
enzymes involved in regeneration of reduced cofactors such as
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FIGURE 1 | Nrf2 pathway and its role in cellular protection. (Nrf2: nuclear factor (erythroid-derived 2)-like 2, ARE: Antioxidant response element, Keap1:
Kelch-like ECH-associated protein 1, sMaf: Small Maf proteins, CREB: cyclicAMP response element-binding protein, ATF - 4: activating transcription factor 4
protein).
glutathione reductase and enzymes involved in reduction of
oxidized cofactors such as thioredoxin reductase. These also
include genes for ferritin required for clearance of metals as
well as redox transporters such as cysteine-glutamine transporter
and enzymes involved in antioxidant production such as HO-
1 (Rojo et al., 2014). Triterpenoids can activate Nrf2 by disso-
ciating Keap1 from Nrf2 (Figure 1; Liby et al., 2005). Ginseng
active constituents include triterpenes as previously described;
thus ginseng can also upregulate ARE pathway-mediated neuro-
protection. Hwang and Jeong (2010) previously suggested that
Rb1 would be protective in SH-SY5Y cells via an ER-dependent
Gbeta1/PI3K/Akt-Nrf2 signaling pathway. And similarly, Du et al.
(2013) proposed that the potential beneficial effect of Ginseng
Rb1 would be via Akt/Nrf2 in the human SK-N-SH dopaminergic
cell line.
Ginsenoside Re, a ginseng saponin can increase the activity
of SOD and glutathione peroxidase, and subsequently allevi-
ate oxidative stress when administered to transient MCAO rat
models as described by Zhou et al. (2006). It also decreases
the amount of malondialdehyde, which is an oxidative stress
marker. Ginsenoside Rd, similar to ginsenoside Rb1, can alleviate
oxidative stress induced damage to DNA, RNA, proteins, and
lipids, and it also preserves endogenous antioxidant activities in
vivo. They found that on administering 50 mg/kg IP ginseno-
side Rd to transient MCAO mice and rat models respectively,
there was a decrease in the infarct volumes and an improve-
ment in behavioral tests (Ye et al., 2011b,c). Ye et al. also
used an in vitro mitochondrial model (intact nonsynaptosomal
mitochondria obtained from rats) to show that ginsenoside
Rd protects mitochondria from calcium-induced mitochondrial
swelling or damage by a decrease in production of ROS (Ye
et al., 2011d). Compound K also attenuates oxidative stress in
post-ischemic rats by decreasing ROS production by microglia
by attenuating NADPH oxidase, which is inhibited by car-
bon monoxide, a product of HO-1 activity (Nakahira et al.,
2006; Park et al., 2012). Kim et al. administered ethanolic
Panax Ginseng extracts IP at a dose of 200 mg/kg to tran-
sient forebrain ischemia rat models whereas Ban et al. adminis-
tered 100 mg/kg Korean red ginseng orally to transient MCAO
rat models (Kim et al., 2009; Table 1).
GINSENG POTENTIAL OTHER BENEFICIAL EFFECTS
Additionally, ginsenosides can attenuate autophagy, a process in
which cells degrade dysfunctional cellular components to survive
stressful conditions, the deregulation of which can be seen in
disease conditions. Ischemic neuronal death is associated with
an increase in autophagy via the formation of autophagosomes
(Wen et al., 2008). Lu et al. demonstrated that ginsenoside Rb1
can decrease autophagy via a decrease in the proteins associated
with it such as microtubule-associated protein 1A light chain
3 (LC3), Beclin 1 (Lu et al., 2011). An intranasal administra-
tion of 12.5 mg/kg ginsenoside Rb1 to transient MCAO rat
models was used that also exerted significant brain targeting
effects due to direct passage of ginsenoside Rb1 to the brain
from the nose through the olfactory epithelium (Lu et al.,
2011).
Neurogenesis might also be a reasonable explanation. In
the event of ischemic insult to the brain, neuronal precursors
migrate to that area, to replace the damaged neurons (Par-
ent et al., 2002). Ginsenoside Rb1 increases the numbers of
these neuronal precursors, which can cause recovery of neu-
ral behavior post-ischemia (Gao et al., 2010). Zheng et al.
suggested a role for ginseng total saponins in the prolifera-
tion of endogenous neural stem cells which can help in neu-
ronal regeneration that can overcome neuronal loss induced
deficits seen due to permanent ischemia in rats. They gave
IP ginseng total saponins to rats at a dosage of 25 mg/kg
and observed a decrease in the Neurological Deficit Score
(NDS; Zheng et al., 2011). Such a hypothesis has attracted
much attention; although, one should remain realistic about
the hope of reestablishing all neuronal connections in an adult
brain.
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Preservation of energy metabolism in the brain post-stroke is
a possible pathway for neuroprotective effects of ginseng in the
brain. Ye et al. showed that ginsenoside Rd post-ischemia can
preserve the mitochondrial electron transport chain in mice brain
(ischemic cortex and striatum), and thus sustain energy genera-
tion (Ye et al., 2011b). It also significantly decreases the anaerobic
glycolysis end-product, lactate, and increases aerobic glycolysis
and thus its end-product, pyruvate, thus improving the energy
status of the brain (Ye et al., 2011d). Ginsenoside Re has been
shown to improve the fluidity of the mitochondrial membrane by
reducing its microviscosity because fluidity of the mitochondrial
membrane is important for energy generation (Zhou et al., 2006).
Black ginseng has been suggested to help prevent vascular
dementia potentially by increasing hippocampal choline acetyl-
transferase activity, which increases acetylcholine levels. Park et al.
administered 100, 400 mg/kg black ginseng orally to transient
MCAO rat models and noticed an improvement in the Morris
water maze test. To get black ginseng, the roots are steamed and
dried a number of times, which has been suggested to increase the
level of saponins (Park et al., 2011). Endothelial dysfunction is one
of the underlying pathophysiologies of the vascular diseases such
as stroke and myocardial infarction; it is basically the disruption
of endothelial homeostasis, making it pro-inflammatory and pro-
thrombotic, which causes a reduction in vasodilation (Endemann
and Schiffrin, 2004). Endothelium-dependent vasodilation can
be impaired by various factors, including elevated levels of
homocysteine in the blood that impairs the endothelium by
producing oxidative stress in normotensive subjects as well as
hypertensive patients (Virdis et al., 2001). Ginsenoside Rb1 has
been shown to decrease homocysteine-induced, endothelium-
dependent vasodilatation when administered to coronary arteries
harvested from pig’s heart at a dosage of 10 µM (Zhou et al.,
2005), and inhibition of endothelial proliferation when admin-
istered to a mouse lymph node endothelial cell line (SVEC4-10)
and human umbilical vein endothelial cells at a dose of 10 µM
(Ohashi et al., 2006). Lan et al., through both in vivo and in
vitro experiments using male rats and human umbilical vein
endothelial cells, suggested that ginsenoside Rb1 actions might
be due to a decrease in homocysteine-induced impairment of
NOS, thus increasing NO, which is a vasodilator; subsequently, it
can prevent homocysteine-induced endothelial dysfunction (Lan
et al., 2011). Ohashi et al. showed that ginsenoside Rb1 can inhibit
homocysteine-induced ROS production from endothelial cells;
subsequently, it can prevent homocysteine inhibition on endothe-
lial proliferation (Ohashi et al., 2006). Ginsenoside Rb1 can thus
prevent stroke in mice. In short, ginseng’s neuroprotective effects
in cerebral ischemia are attributed to its anti-inflammatory and
anti-apoptotic effects, along with attenuation of oxidative stress
of the neurons (Xu et al., 2014; Figure 2).
Ginsenoside Rd, due to its highly lipophilic nature, can diffuse
across biological membranes, possibly also across the blood brain
barrier (Ye et al., 2011d). Ginsenoside Rd efficacy was also pro-
posed by a human randomized, double-blind, placebo controlled
multicenter trial that showed ginsenoside Rd causes a reduction
in the National Institutes of Health stroke scale at 15 days post-
ischemic stroke, but it did not improve overall neurological func-
tioning (Liu et al., 2009). Although the trial results are somewhat
encouraging, it had several limitations such as small sample size,
no post-discharge follow up, and delayed administration of drug
post-stroke at 72 h (Liu et al., 2009). Furthermore, biomarkers,
circulating blood levels, etc., would be helpful for further studies.
GINSENG PROTECTION IN SUBARACHNOID HEMORRHAGE
(SAH)
Ginsenoside Rb1 treatment has also been shown to reduce post-
SAH brain edema in rats (Li et al., 2011). It also caused a signif-
icant decrease in vasospasms in the basilar artery, as well as in its
FIGURE 2 | Summary of mechanisms of action of ginseng and its
constituents in stroke. (IL-6: Interleukin-6, NF-κB: Nuclear factor-κB, AP-1:
Activator protein-1, iNOS: Inducible nitric oxide synthase, COX-2:
Cycloxygenase-2, MAPK: Mitogen-activated protein kinase, HO-1: Heme
oxygenase-1, AIF: apoptosis inducing factor, GDNF: Glial-derived neurotrophic
factors, BDNF: Brain-derived neurotrophic factor, SOD: Superoxide
dismutase, GP: Glutathione peroxidase, GST: Glutathione S-transferase, GR:
Glutathione reductase, MDA: Malondialdehyde, NADPH: Nicotinamide
adenine dinucleotide phosphate-diaphorase, NQO1: NADPH quinone
reductase 1, ROS: Reactive oxygen species, TrxR: Thioredoxin reductase).
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lumen thickness. Vasospasm is the most common complication
of SAH and leads to delayed ischemic deficits (Venkatesh Aiyagari
and Diringer, 2005); thus ginsenoside Rb1 would also prevent
the delayed ischemic deficits. A significant improvement was also
noticed in the neuronal functioning in rats post-SAH (Li et al.,
2011).
GINSENG NEUROPROTECTION IN TRAUMATIC BRAIN
INJURY (TBI)
TBI is another acute neurological disorder and to the same extent
incorporates components of both hemorrhagic and ischemic
stroke. TBI and concussions are major public health problems
and causes of mortality in neurological conditions, notably
in young adults. Various preclinical rat studies have demon-
strated the neuroprotective effects of ginseng in TBI; how-
ever, no rigorous human studies are available. Ginseng total
saponins decrease post-TBI brain edema, which is partly respon-
sible for the focal neurological deficits seen in TBI (Xia et al.,
2012). It also decreases the pro-inflammatory cytokines IL-6
and IL-1β, and increases IL-10, which is anti-inflammatory (Xia
et al., 2012). It has been shown to alleviate oxidative stress
post-TBI by increasing SOD and iNOS activity and decreas-
ing malondialdehyde levels in the brain (Xia et al., 2012).
Its anti-apoptotic activities can be described by the finding
that it reduces caspase-3 and BAX expression and increases
Bcl-2 expression (Xia et al., 2012). Other researchers have
also demonstrated beneficial effects of ginseng in TBI by sim-
ilar mechanisms stated above (Ji et al., 2005; Kumar et al.,
2014).
GINSENG POTENTIAL IN VARIOUS CHRONIC
NEURODEGENERATIVE DISORDERS
Multiple clinical as well as translational studies have demon-
strated the effectiveness of ginseng in various neurological dis-
orders, both acute (ischemic and hemorrhagic stroke, TBI) and
chronic (Alzheimer, Huntington and Parkinson) diseases. The
main emphasis here is on preclinical chronic models and most
specifically on acute preclinical models, i.e., stroke.
Alzheimer disease is the most common cause of dementia in
many industrialized countries (Alzheimer’s Association, 2013).
In preclinical models, ginsenoside Rb1 and ginsenoside Rg1 can
increase the formation of new synapses (Mook-Jung et al., 2001).
It was proposed that ginsenoside Rg1 would be involved in
the regulation of the proliferation of hippocampal progenitor
cells and this effect may serve as one of the elementary mech-
anisms underlying its nootropic and anti-aging actions (Shen
and Zhang, 2004). When treated with Rg1, the NO content
and NOS activity in the cerebral cortex of old rats decreased
(Li et al., 1997). Fang et al. showed that ginsenoside Rg1 is
protective for the neurons by impairing cerebral β amyloid
accumulation in Alzheimer mouse models (Fang et al., 2012).
Thus, ginseng can support neuronal survival and further promote
neuronal growth and differentiation, which plays an important
role in the diminution of Alzheimer disease pathology. Briefly,
Ginsenoside Rb1 enhances cognition through up-regulation of
hippocampal neuronal genesis (Liu et al., 2011). Along with
cell genesis, synaptic plasticity also plays an important role in
memory (Gerrow and Triller, 2010). Synaptic plasticity is the
capability of synapses to change their strength over time in
response to an alteration in their activities (Hughes, 1958).
The mammalian target of rapamycin (mTOR) signaling path-
way upregulates synaptic plasticity-related protein synthesis in
the hippocampus, and long-term ginsenoside Rg1 treatment up-
regulates mTOR signaling; thus ginsenoside Rg1 was suggested
to contribute to synaptic plasticity and can prevent dementia
(Yang et al., 2013). Aprikyan et al. showed that aging related
dementia is associated with a significant decrease in glutamate
release (Aprikyan and Gekchyan, 1988). Ginsenoside Rg1 or
ginsenoside Rb1 can increase glutamate release from rat cor-
tical synaptosomes by acting as presynaptic facilitators for 4-
aminopyridine evoked glutamate release (Chang et al., 2008).
Although various studies have shown an ameliorating effect of
ginseng on cognitive decline, a Cochrane review by Geng et al.
showed no reassuring evidence to prove the beneficial effects of
Panax ginseng on cognition or in patients with dementia (Geng
et al., 2010).
Parkinson pathology is another neurodegenerative disorder
that is characterized by bradykinesia, cog-wheel rigidity, and
resting tremor and can lead to dementia. Its pathophysiology
involves the degeneration of dopaminergic neurons in substantia
nigra, leading to a decrease in dopamine, which causes the symp-
toms. Ginsenoside Rb1 and ginsenoside Rg1 have been shown to
support energy metabolism and preserve the structural integrity
of the dopaminergic neurons in Parkinson (Radad et al., 2004).
Ginsenoside Rg1 can also act against MPTP-induced apoptosis by
increases in Bcl-2 formation (Chen et al., 2002).
Huntington’s disease is an inherited neurodegenerative disease
with symptoms ranging from choreiform movement disorder
(dyskinesia) to dementia and behavioral changes. At low doses,
ginsenoside Rb1, ginsenoside Rc, and ginsenoside Rg5 have been
shown to attenuate neuronal apoptosis induced by glutamate in
an in vitro Huntington Disease model (Wu et al., 2009).
CONCLUSION
The role of ginseng in neuroprotection has been an interesting
topic of research for a very long time. Various mechanisms involv-
ing ginseng’s neuroprotective effects in stroke have been proposed
up to this point that are basically focused on maintenance of
homeostasis, anti-inflammation, anti-oxidative stress and anti-
apoptosis. A more detailed characterization of the cellular and
molecular pathways is required. We propose that the modulation
of the Nrf2 pathway may be a way by which ginseng can build
cell and organ resistance to a multitude of stresses. By inducing
the expression of antioxidant and phase II detoxifying genes, Nrf2
activates a wide range of cell defense processes, thereby improving
on the efficiency of cells to detoxify and eliminate various harmful
substances. Also, by better understanding ginseng’s mechanism of
action, it would help for the optimal design of clinical research
outcomes. Dose-response relationships and therapeutic windows
for ginseng and its sub-components require more elaboration.
The preparation of ginseng and its compounds is highly vari-
able; standardization of the preparations is required to com-
pare and analyze different studies, along with pharmacokinetic
and pharmacodynamic studies. Most of the preclinical studies
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have been performed in vitro or in vivo on rats or mice. Thus,
larger animals and species closer to humans would likely help
translational outcomes. Very few rigorous double blinded clinical
trials have been performed to date with standardized ginseng
extracts. Large-scale, randomized, double-blinded clinical trials
with clear defined outcomes over time are required to delin-
eate the efficacy of ginseng in various neurological disorders in
humans.
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